Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6727MR)

This product GTTS-WQ6727MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ6727MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11928MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ2600MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ1024MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ9665MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ12725MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ8506MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ467MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ10569MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY­3074828
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW